Trial Profile
Effect of LY3314814 on the Pharmacokinetics of Dabigatran in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 Dec 2019
Price :
$35
*
At a glance
- Drugs Lanabecestat (Primary) ; Dabigatran etexilate
- Indications Alzheimer's disease
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 18 Dec 2019 Results, assessing the interaction between dabigatran etexilate and lanabecestat when they are taken together, published in the Journal of Clinical Pharmacology
- 24 Mar 2018 Results presented at the 119th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 25 Jan 2016 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.